Barclays’s Akero Therapeutics AKRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$28.5M Buy
533,416
+410,253
+333% +$21.9M 0.01% 685
2025
Q1
$4.99M Sell
123,163
-9,674
-7% -$392K ﹤0.01% 1422
2024
Q4
$3.7M Buy
132,837
+5,169
+4% +$144K ﹤0.01% 1813
2024
Q3
$3.66M Buy
127,668
+71,652
+128% +$2.06M ﹤0.01% 1742
2024
Q2
$1.32M Sell
56,016
-14,665
-21% -$344K ﹤0.01% 1961
2024
Q1
$1.79M Sell
70,681
-175,593
-71% -$4.43M ﹤0.01% 2024
2023
Q4
$5.75M Buy
246,274
+114,828
+87% +$2.68M ﹤0.01% 1389
2023
Q3
$6.65M Sell
131,446
-11,632
-8% -$588K ﹤0.01% 1005
2023
Q2
$6.68M Buy
143,078
+65,854
+85% +$3.07M ﹤0.01% 1073
2023
Q1
$2.95M Sell
77,224
-26,328
-25% -$1.01M ﹤0.01% 1401
2022
Q4
$5.67M Buy
103,552
+102,364
+8,616% +$5.61M ﹤0.01% 1047
2022
Q3
$40K Sell
1,188
-10,890
-90% -$367K ﹤0.01% 3721
2022
Q2
$114K Buy
12,078
+4,468
+59% +$42.2K ﹤0.01% 3412
2022
Q1
$107K Sell
7,610
-27,820
-79% -$391K ﹤0.01% 3633
2021
Q4
$749K Buy
35,430
+21,362
+152% +$452K ﹤0.01% 2346
2021
Q3
$315K Buy
14,068
+8,592
+157% +$192K ﹤0.01% 2792
2021
Q2
$136K Sell
5,476
-7,281
-57% -$181K ﹤0.01% 3038
2021
Q1
$369K Buy
12,757
+6,819
+115% +$197K ﹤0.01% 2828
2020
Q4
$153K Sell
5,938
-2,231
-27% -$57.5K ﹤0.01% 2820
2020
Q3
$252K Sell
8,169
-9,230
-53% -$285K ﹤0.01% 2619
2020
Q2
$434K Buy
17,399
+14,617
+525% +$365K ﹤0.01% 2398
2020
Q1
$59K Sell
2,782
-2,236
-45% -$47.4K ﹤0.01% 3025
2019
Q4
$112K Buy
5,018
+2,361
+89% +$52.7K ﹤0.01% 3415
2019
Q3
$61K Buy
+2,657
New +$61K ﹤0.01% 3614